Anzeigenschluss: 19.06.2025
Erscheinungstermin: 14.07.2025
Hämatologie
Hämatologie
DLBCL
Abramson JS et al.
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
PTCL
Tournilhac O et al.
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma)
Mantelzelllymphom
Wang M et al.
Ibrutinib plus venetoclax in relapsed or refractory mantle celllymphoma (SYMPATICO): a multicentre, randomised,double-blind, placebo-controlled, phase 3 study
CLL
Brown JR et al.
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
DLBCL
Bartlett NL et al.
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
MBCL
Martelli M et al
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results
Statement: ASCO
Highlights vom ASCO zur Hämatoonkologie
S3-Leitlinie CLL
Was bringt das Update Neues?
Kongressbericht EBTM
Bericht vom 51. Jahrestreffen der EBMT
Gynäkoonkologie
Brustkrebs
Meattini I et al.
Single-modality endocrine therapy versus radiotherapy afterbreast-conserving surgery in women aged 70 years and olderwith luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial
Brustkrebs
Hortobagyi GN et al.
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial
Brustkrebs
Di Meglio A et al.
Experiences and preferences about information on treatment-related side effects among patients with early breast cancer
Statement: ASCO
Highlights vom ASCO zur Gynäkoonkologie
Kongressbericht ESMO BCC
Neue Daten aus München zu Brustkrebs
Gastroonkologie
GIST
Blay JY et al.
A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
Ösophaguskarzinom
Hoeppner J et al.
Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer
Rektumkarzinom
Baron D et al.
A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial
Ösophaguskarzinom
Van der Wilk BJ et al.
Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial
CRC
Sørensen HT et al.
More vs Less Frequent Follow-Up Testing and 10-Year Mortality in Patients With Stage II or III Colorectal Cancer: Secondary Analysis of the COLOFOL Randomized Clinical Trial
Statement: ASCO
Highlights von der ASCO-Jahrestagung zur Gastroonkologie
Pneumoonkologie
NSCLC
Ahn M-J et al.
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
NSCLC
Sun H, Li M, Huang W, et al.
Thoracic radiotherapy improves the survival in patients with EGFR-mutated oligo-organ metastatic non–small cell lung cancer treated with epidermal growth factor receptor–tyrosine kinase inhibitors: a multicenter, randomized, controlled, phase III trial
NSCLC
Yue D et al.
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
Kongressbericht DGP
Bericht vom 65. Kongress der Deutschen Gesellschaft für Pneumologie
Uroonkologie
Urothelkarzinom
Galsky MD et al.
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274
Blasenkarzinom
Powles T et al.
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
Prostatakarzinom
Ola IO et al.
Long-term Risk of Prostate Cancer Mortality Among Men with Baseline Prostate-specific Antigen Below 3 ng/ml: Evidence from the Finnish Randomized Study of Screening for Prostate Cancer
Dermatoonkologie
Melanom
Mayer KE et al.
Survival after cessation of immunotherapies in melanoma: A systematic review and meta-analysis
Melanom
Syeda MM et al.
Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial
Interview: Melanom
Prof. Dirk Schadendorf über die Änderungen der S3-Leitlinie zum malignen Melanom
Kongessbericht EADO
Neues vom Kongress der European Association of Dermato-Oncology
Supportivtherapie
Bewegung und Fatigue
Mulero Portelo AL et al.
Effect of low- and moderate-intensity endurance exercise on physical functioning among breast cancer survivors: a randomized controlled trial
CIPN
Ran L et al.
Effects of intermittent hand–foot hypothermia therapy on chemotherapy-induced peripheral neurotoxicity
CINV
Shen G et al.
Effect of Adding Electroacupuncture to Standard Triple Antiemetic Therapy on Chemotherapy-Induced Nausea and Vomiting: A Randomized Controlled Clinical Trial
Fatigue
Erfassung und Behandlung krebsassoziierter Fatigue
Allgemeine Onkologie
Sarkome
Mowery YM et al.
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial
Herzgesundheit
Weaver KA et al.
Effectiveness of a Cardiovascular Health Electronic Health Record Application for Cancer Survivors in Community Oncology Practice: Results From WF-1804CD
Antibiotikaresistenzen
Gupta V et al.
Incidence and prevalence of antimicrobial resistance in outpatients with cancer: a multicentre, retrospective, cohort study
MRD
Messbare Resterkrankung: Muss man wirklich auch die letzte Krebszelle eliminieren?
Patientenzentrierte Onkologie
Empowerment durch PROM: der Kontext ist entscheidend für die Wirksamkeit
Wie wirkt was?
Menin-Inhibitoren
*Die Redaktion behält sich aktuelle Änderungen vor.